Synopsis: Global technology stocks have come under pressure, bringing defensive sectors back into focus. But among Varun Beverages, Sun Pharma and Apollo Hospitals, which business is better placed during uncertain markets? A closer look at their growth drivers, risks and business models shows that not all defensive stocks offer the same level of stability.
When technology stocks start falling, investors often look for businesses that are less dependent on market excitement and more dependent on everyday demand. In such phases, defensive stocks usually come back into focus because their products and services are needed even when the market mood is weak.
This is where Varun Beverages, Sun Pharma and Apollo Hospitals become interesting. One sells beverages, one sells medicines and one runs hospitals, pharmacies and healthcare services. All three have demand linked to consumption or healthcare, but they are not defensive in the same way. Their growth drivers, risks and earnings quality are very different.
Varun Beverages Ltd
Varun Beverages is a simple business to understand. It makes and distributes beverages, mainly for PepsiCo, across India and international markets. The defensive argument here comes from daily consumption. People may delay buying expensive gadgets or cars during uncertain times, but small-ticket beverages remain easier to buy.
In Q1 CY2026, the company reported a strong operating performance. Consolidated sales volumes grew 16.3 percent year-on-year. India volumes grew 14.4 percent, while international volumes grew 21.4 percent. Revenue increased 18.1 percent year-on-year to Rs. 65,742 million and EBITDA improved 21 percent year-on-year to Rs. 1,528.9 crore.
This shows that demand was healthy, and the company was not only growing through pricing but also through volumes. For a consumer company, volume growth is important because it shows that more products are actually being sold.
What Is Working For VBL?
The biggest positive for VBL is execution. The company is expanding manufacturing capacity, investing in chilling infrastructure and widening distribution. These things matter because beverages are impulse products. If the bottle is cold and available near the customer, sales become easier.
Management also spoke about pack upsizing, selective price-point launches and new products in energy and juice-based drinks. Energy drinks are becoming an important growth area. Management said Ad-Rush and Sting Classic had seen stronger-than-expected demand, and Sting Classic in PET bottles was launched in April.
The international business is another growth driver. The company completed the Twizza acquisition in South Africa through BevCo and also entered into an agreement to acquire Crickley Dairy, subject to approvals. This can help VBL broaden its portfolio beyond carbonated drinks and build a larger African business over time.
Where Is The Risk?
The risk is that VBL is more of a growth defensive than a pure defensive. The business is linked to weather, summer demand, distribution execution and input costs. Beverages also face competition, and the company itself said the market is seeing more activity from competitors.
Water is another area where management is careful. It said it does not want to push water through heavy discounts because water is more commodity-like and margins need to be protected. This is sensible, but it also means growth cannot come at any cost. VBL is a strong consumer company, but its earnings can be more affected by factors like weather and consumer demand than some other defensive businesses.
Sun Pharmaceutical Industries Ltd
Sun Pharma looks more defensive compared to VBL. Medicines are not discretionary. Patients need treatment across market cycles, and a large pharma company with global scale usually has more stable demand than most sectors.
In Q4 FY26, Sun Pharma reported sales of Rs. 14,560 crore, growing 13.6 percent year-on-year. Gross margin was 80.8 percent. EBITDA stood at Rs. 3,954 crore, up 6.4 percent year-on-year, with an EBITDA margin of 27.1 percent. Reported net profit was Rs. 2,714 crore.
For FY26, sales were Rs. 58,220 crore, growing 11.9 percent. EBITDA was Rs. 17,731 crore, up 16.1 percent, with an EBITDA margin of 30.3 percent. Adjusted net profit for the year was Rs. 10,929 crore. The company also had a strong balance sheet, with net cash of USD 3.2 billion.
What Is Working For Sun Pharma?
The biggest shift at Sun Pharma is the rising contribution from innovative medicines. In Q4 FY26, innovative medicine sales grew 20.1 percent to USD 354 million. For the full year, global innovative medicine sales stood at USD 1.42 billion, growing 16.8 percent. This business accounted for 22.2 percent of Sun Pharma’s sales in the quarter.
This matters because innovative medicines can improve the quality of growth. They are not the same as plain generic drugs, where competition and pricing pressure can hurt margins. Ilumya remains a key product, with FY26 global sales of US$ 796 million, growing 16.7 percent.
India is also doing well. India formulation sales were Rs. 4,836 crore in Q4, growing 14.8 percent. For the full year, India formulation sales were Rs. 19,290 crore, growing 14 percent. Sun Pharma said it is ranked number one in the Indian pharmaceutical market with 8.4 percent share.
Where Is The Risk?
The main risk is that Sun Pharma is no longer just a simple India pharma story. It is becoming a larger global pharma company. That brings more regulatory, R&D and acquisition-related complexity.
The company has also announced the Organon acquisition. The deal can make Sun bigger globally, but it will also increase integration work. Management said an integration management office has been set up and regulatory filings are in progress, with the acquisition expected to complete in Q4 FY27.
Margins also need watching. Q4 EBITDA margin fell to 27.1 percent from 31.9 percent in Q3. Management said this was due to lower milestone income, seasonality, lower contribution from lenalidomide and higher spends in some geographies including the US. So, even a defensive business can have quarterly margin pressure.
Still, compared to Varun Beverages, Sun Pharma has a cleaner defensive argument because healthcare demand, global diversification, high margins and net cash all support the case.
Apollo Hospitals Enterprises
Apollo Hospitals is also defensive because hospital demand is linked to healthcare needs. People do not stop needing surgeries, diagnostics or medicines because the stock market is weak. But Apollo is different from Sun Pharma because it is also an execution-heavy business. Hospitals need beds, doctors, equipment, occupancy and steady patient flow.
In Q4 FY26, Apollo’s consolidated EBITDA stood at Rs. 1,011 crore, growing 31 percent year-on-year. Consolidated PAT was Rs. 579 crore, up 36 percent year-on-year. For FY26, consolidated revenue stood at Rs. 25,229 crore, growing 16 percent year-on-year. Consolidated EBITDA was Rs. 3,769 crore, up 25 percent, while PAT grew 34 percent to Rs. 1,942 crore.
The hospital business remained strong. Healthcare services revenue in Q4 was Rs. 3,268 crore, growing 16 percent year-on-year. Occupancy stood at 68 percent, while established units were at 69 percent. Average revenue per inpatient was Rs. 187,208.
What Is Working For Apollo?
Apollo has three engines: hospitals, Apollo HealthCo and AHLL. This makes the business broader than only hospitals. The hospital business benefits from high-acuity specialties such as cardiac, oncology, neurosciences, gastro and orthopedics. These areas usually have higher clinical intensity and better revenue per patient.
Apollo HealthCo is also improving. In Q4 FY26, HealthCo revenue was Rs. 2,848 crore, growing 20 percent year-on-year. Online business cash losses fell sharply to Rs. 16 crore from Rs. 80 crore in Q4 FY25. HealthCo EBITDA rose to Rs. 156 crore from Rs. 36 crore last year.
AHLL also performed well, with revenue growing 24 percent and EBITDA growing 58 percent in Q4 FY26. Diagnostics was a key driver, growing 52 percent year-on-year.
Where Is The Risk?
Apollo is attractive, but it is not the simplest defensive stock. The company is expanding hospitals, improving digital health economics, restructuring HealthCo and combining Apollo Cradle and Fertility with Cloudnine. These steps can create value, but they also add moving parts.
New hospitals can take time to mature. Digital health has improved sharply, but investors still need to track whether the reduction in losses continues. The planned demerger of the omni-channel pharmacy and digital health business is also important, and management expects the process to be completed by Q4 FY27. So, Apollo is a strong healthcare platform, but it has more execution risk than Sun Pharma.
Which Defensive Stock Looks Better?
If the question is about pure defensive comfort during a global tech sell-off, Sun Pharma looks like the better opportunity among the three. It has a large global business, strong India presence, high margins, rising innovative medicine sales and a net cash balance sheet. Its products are also more need-based than discretionary.
Apollo Hospitals comes second. It is a powerful healthcare ecosystem with strong growth across hospitals, HealthCo and AHLL. But it has more execution layers because hospital expansion, digital health profitability and restructuring all need to work together.
Varun Beverages is a strong consumer growth story, but it is less defensive than the other two. Its business depends more on seasonality, beverages demand, competition, distribution and international expansion. It can do very well in a healthy consumption cycle, but it may not offer the same defensive comfort as healthcare.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
